(NASDAQ: BFRI) Biofrontera's forecast annual revenue growth rate of 14.73% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.58%.
Biofrontera's revenue in 2026 is $46,175,000.On average, 4 Wall Street analysts forecast BFRI's revenue for 2026 to be $699,070,833, with the lowest BFRI revenue forecast at $667,955,141, and the highest BFRI revenue forecast at $723,606,930. On average, 4 Wall Street analysts forecast BFRI's revenue for 2027 to be $810,077,365, with the lowest BFRI revenue forecast at $775,798,120, and the highest BFRI revenue forecast at $836,603,678.
In 2028, BFRI is forecast to generate $1,035,640,141 in revenue, with the lowest revenue forecast at $995,033,791 and the highest revenue forecast at $1,066,102,329.